Kestra Medical insider sells shares to cover taxes

Kestra Medical Technologies, Ltd. insider Traci S. Umberger, a director and officer, reported selling a total of 22229 Common Shares in three open-market or private transactions on July 30, July 31, and August 3, 2026.

Rhea-AI Filing Summary

Kestra Medical Technologies, Ltd. insider Traci S. Umberger, a director and officer, reported selling a total of 22229 Common Shares in three open-market or private transactions on July 30, July 31, and August 3, 2026. Footnotes state these were nondiscretionary sell-to-cover sales required to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units, executed at weighted-average prices within ranges from about $22.17 to $24.28 per share.

Insider Trade Summary

Net Seller: 22,229 shares

Net Sell 3 txns

Insider Umberger Traci S

Role See Remarks

Sold 22,229 shs ($513K)

Type	Security	Shares	Price	Value
Sale	Common Shares F1, F4	7,590	$23.8553	$181K
Sale	Common Shares F1, F3	8,752	$22.6048	$198K
Sale	Common Shares F1, F2	5,887	$22.7437	$134K

Holdings After Transaction: Common Shares — 199,405 shares (Direct)

Footnotes (4)

1. F1. The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.
2. F2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.2400 to $23.1700. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
3. F3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.1700 to $22.9200. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
4. F4. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.6500 to $24.2800. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Key Figures

Total shares sold: 22229 shares Shares sold 2026-07-30: 5887 shares at $22.7437 Shares sold 2026-07-31: 8752 shares at $22.6048 +1 more

4 metrics

Total shares sold 22229 shares Aggregate Common Shares sold in three nondiscretionary sell-to-cover transactions on July 30, July 31, and August 3, 2026

Shares sold 2026-07-30 5887 shares at $22.7437 Common Shares sold on 2026-07-30; weighted average price with range $22.2400–$23.1700 per share

Shares sold 2026-07-31 8752 shares at $22.6048 Common Shares sold on 2026-07-31; weighted average price with range $22.1700–$22.9200 per share

Shares sold 2026-08-03 7590 shares at $23.8553 Common Shares sold on 2026-08-03; weighted average price with range $23.6500–$24.2800 per share

Key Terms

sell to cover, restricted stock units, weighted average price

3 terms

sell to cover financial

"pursuant to sell to cover transactions to satisfy tax withholding obligations"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

restricted stock units financial

"tax withholding obligations in connection with the vesting and settlement of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider share sales did Kestra Medical Technologies (KMTS) report in this Form 4?

Traci S. Umberger reported selling 22229 Kestra Medical Common Shares across three transactions on July 30, July 31, and August 3, 2026. These were nondiscretionary sell-to-cover trades executed in open-market or private transactions to satisfy tax withholding from vested restricted stock units.

Why did Traci S. Umberger sell Kestra Medical Technologies (KMTS) shares?

The filing explains that each sale was a nondiscretionary sell-to-cover transaction. Shares were required to be sold to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units, rather than discretionary open-market profit-taking.

How many KMTS shares were sold in each reported insider transaction?

Umberger sold 5887 shares on July 30, 8752 shares on July 31, and 7590 shares on August 3, 2026. In total, these nondiscretionary tax-related sales covered 22229 Common Shares of Kestra Medical Technologies, Ltd.

At what prices were Kestra Medical Technologies (KMTS) shares sold in these insider trades?

Each trade used a weighted average price. On July 30, prices ranged from $22.2400–$23.1700; on July 31, from $22.1700–$22.9200; and on August 3, from $23.6500–$24.2800, with corresponding weighted-average prices in the low-to-mid $20s per share.

Were the KMTS insider sales made under a Rule 10b5-1 trading plan?

The Rule 10b5-1 checkbox in the filing was not selected. Instead, a footnote states the transactions were nondiscretionary sell-to-cover sales required to meet tax withholding obligations related to the vesting of restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/03/2026 - 07:29 PM Accepted by SEC EDGAR 08/03/2026 - 07:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Umberger Traci S

(Last) (First) (Middle)

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WASHINGTON 98033

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	07/30/2026		S(1)		5,887	D	$22.7437(2)	215,747	D
Common Shares	07/31/2026		S(1)		8,752	D	$22.6048(3)	206,995	D
Common Shares	08/03/2026		S(1)		7,590	D	$23.8553(4)	199,405	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.

2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.2400 to $23.1700. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.1700 to $22.9200. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

4. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.6500 to $24.2800. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Remarks:

General Counsel and Chief Adminstrative Officer

	/s/ Traci S. Umberger	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)